Policy Updates on Access to and Affordability of Innovative Medicines in China
Abstract
In China, efforts to qualify innovative medical products for reimbursement used to be subject to substantial delays after regulatory approval due to fiscal and bureaucratic barriers. In this review, we surveyed the Chinese government’s most recent initiatives to improve access to innovative medicines from both the regulatory and the reimbursement aspects, which not only accelerated the launching of drugs in the Chinese market but also expanded the reimbursement coverage of such products. We also provided a discussion of the current challenges.
Areas Covered
We provided a comprehensive review of the updates in China’s national reimbursement listing policies of medicines.
Authors
Yawen Jiang Xiaoning He Gordon G. Liu Jing Wu